This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Signs Point to MAP Pharma Drug Rejection

MOUNTAIN VIEW, Calif. ( TheStreet) -- No official word yet but U.S. regulators have more than likely rejected an inhaled migraine drug from MAP Pharmaceuticals (MAPP).

How do I know this? In response to a question about the regulatory status of Levadex, an FDA spokesperson told me via email, "The company [MAP Pharma] should be able to provide you with an update on Levadex."

FDA does not publicly announce drug rejections, therefore, the most likely scenario is that regulators told MAP Pharma earlier today that Levadex cannot be approved. It's up to MAP Pharma to disclose the Levadex rejection.

"The company will update publicly when ready," said a MAPP Pharma spokesperson via an email sent at 2 pm EDT. More than two hours later, we're still waiting for MAP Pharma to say something about Levadex. If the drug were approved, MAP Pharma would be quick with an announcement.

MAP Pharma shares were up 7% to $17.14 Monday before being halted just before 2 pm EDT. The stock's market value has increased 30% this year on investor confidence in Levadex's approval. A chorus of sell-side analysts predicting the same certainly helped.

MAP's stock gains will disappear if/when the FDA's rejection of Levadex is confirmed. How far the stock falls will likely depend on the specific concerns raised by FDA and what the company needs to do in order to resubmit the drug for approval again.

MAP Pharma has about $3.30 per share cash based off its first-quarter burn rate.

Levadex is an inhaled formulation of DHE, a drug already used in intravenous and nasal spray formulations to treat migraines. MAP Pharma developed a simple device that allows patients suffering from acute migraines to inhale the drug into their lungs, thereby accelerating pain relief.

Had Levadex been approved, Allergan (AGN - Get Report) was set to market the drug to pain specialists and neurologists under a marketing partnership signed with MAP Pharma. Nektar Therapeutics> (NKTR - Get Report) was to receive royalties on sales of the drug.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AGN $216.05 -0.94%
NKTR $15.63 -2.20%
AAPL $95.50 2.00%
FB $117.79 -0.66%
GOOG $695.46 -0.39%


Chart of I:DJI
DOW 17,752.14 -139.02 -0.78%
S&P 500 2,065.06 -16.37 -0.79%
NASDAQ 4,775.9440 -41.65 -0.86%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs